General paperEnhancement in the protective qualities of gastric mucus by Ebrotidine (cas 100981-43-9) during duodenal ulcer healing
-
Add time:08/21/2019 Source:sciencedirect.com
1.1. Gastric mucus from duodenal ulcer patients before and following therapy with a new antiulcer agent, Ebrotidine (cas 100981-43-9), at 400, 600 and 800 mg dose was examined for changes in the physicochemical qualities and anti-H. pylori activity.2.2. The results of physical measurements revealed that successful therapy with ebrotidine was accompanied by a 25% increase in gastric mucus viscosity, and a 20% increase in H+ retardation capacity, while its hydrophobicity increased by 11%.3.3. The enhancement in the physical properties of mucus with ebrotidine therapy were also reflected in a marked (2.6-2.9-fold) increase in the proportion of the high molecular weight form of mucin. Furthermore, following therapy with ebrotidine, the gastric mucins showed a 36% higher content of sulfate as compared to that before the therapy.4.4. Assays on the H. pylori aggregating titer of gastric mucin revealed that ebrotidine therapy at all three doses evoked a 4-fold increase in mucin anti-H. pylori activity.5.5. The data demonstrate that duodenal ulcer therapy with ebrotidine leads to a marked improvement in the protective qualities of gastric mucus essential for the maintenance of mucosal integrity and enhances the inherent mucosal defense against H. pylori infection.
We also recommend Trading Suppliers and Manufacturers of Ebrotidine (cas 100981-43-9). Pls Click Website Link as below: cas 100981-43-9 suppliers
Prev:Determination of Ebrotidine (cas 100981-43-9) and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography
Next:General paperInhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: Effect of Ebrotidine (cas 100981-43-9)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Determination of Ebrotidine (cas 100981-43-9) and its metabolites by capillary electrophoresis with UV and mass spectrometry detection08/24/2019
- General paperEffect of Ebrotidine (cas 100981-43-9) on the synthesis and secretion of gastric sulfomucin08/23/2019
- General paperInhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: Effect of Ebrotidine (cas 100981-43-9)08/22/2019
- Determination of Ebrotidine (cas 100981-43-9) and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography08/20/2019
- Ebrotidine (cas 100981-43-9) effect on the proteolytic and lipolytic activities of Helicobacter pylori08/19/2019
- General paperGastric mucosal laminin receptor expression with ulcer healing by Ebrotidine (cas 100981-43-9)08/18/2019
- General paperEnhancement of gastric mucus phospholipid secretion by an antiulcer agent, Ebrotidine (cas 100981-43-9)08/17/2019
- Acute liver injury associated with the use of Ebrotidine (cas 100981-43-9), a new H2-receptor antagonist08/16/2019
- Determination of Ebrotidine (cas 100981-43-9) and its metabolites by micellar electrokinetic capillary chromatography08/15/2019